| Bioactivity | Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel[1][2][3]. | ||||||||||||
| Name | Larotaxel | ||||||||||||
| CAS | 156294-36-9 | ||||||||||||
| Formula | C45H53NO14 | ||||||||||||
| Molar Mass | 831.90 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Larotaxel
CAS: 156294-36-9 F: C45H53NO14 W: 831.90
Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.